Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20 PM ET. The event aims to discuss advancements in treatments for serious diseases, focusing on their lead product, VRDN-001, targeting thyroid eye disease (TED). This condition can cause severe complications, necessitating surgical interventions. A live webcast and replay of the chat will be available on Viridian's website.
Viridian Therapeutics has received FDA clearance for its investigational new drug application for VRDN-002, a novel monoclonal antibody using half-life extension technology. The VRDN-002 is designed for low-volume subcutaneous injection to treat thyroid eye disease (TED). The company plans to initiate a first-in-human Phase 1 clinical trial to assess safety and pharmacokinetics, with results expected in mid-2022. This marks a key developmental milestone as Viridian aims to enhance treatment convenience for TED patients.
Viridian Therapeutics has submitted an IND application to the FDA for VRDN-002, a monoclonal antibody designed for thyroid eye disease. This innovative therapy incorporates half-life extension technology, enabling low-volume subcutaneous administration. The company aims to initiate a Phase 1 clinical trial to assess the drug's safety, tolerability, and pharmacokinetics with results expected in mid-2022. CEO Jonathan Violin emphasized this step is critical for their clinical strategy, alongside upcoming data for VRDN-001.
Viridian Therapeutics has initiated a Phase 1/2 proof-of-concept clinical trial for VRDN-001, a monoclonal antibody targeting the IGF-1 receptor, aimed at treating thyroid eye disease (TED). The trial, which includes healthy volunteers and TED patients, evaluates safety, tolerability, and potential efficacy with top-line data expected in 2Q 2022. This trial follows preclinical data from over 100 oncology patients, suggesting promising safety and pharmacokinetics for VRDN-001, previously known as AVE1642.
Viridian Therapeutics (Nasdaq: VRDN) announced the approval of stock options for 180,000 shares to two new employees, granted as Inducement Grants. These grants, awarded outside of the company's 2016 Equity Incentive Plan, will vest over four years. The exercise price will match the stock's closing price on each employee's Grant Date. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support Viridian's mission of developing treatments for serious diseases, including its leading program targeting thyroid eye disease.
Viridian Therapeutics has received FDA clearance for its Investigational New Drug application for VRDN-001, a monoclonal antibody aimed at treating thyroid eye disease (TED). The company plans to initiate a Phase 1/2 proof of concept trial involving randomized, placebo-controlled cohorts of TED patients, assessing the drug's potential to improve symptoms rapidly. Expected top-line clinical data is anticipated in the second quarter of 2022. CEO Jonathan Violin emphasizes this milestone as the start of a busy year for the company's development pipeline.
Viridian Therapeutics (NASDAQ: VRDN) announced its IND application for VRDN-001, an antibody for Thyroid Eye Disease (TED), with proof of concept data expected in Q2 2022. The second candidate, VRDN-002, is on schedule for IND filing by year-end 2021. Following a successful public offering in September 2021, the company has a strong cash position of $213.8 million, funding operations into 2024. Third-quarter net loss was $14.03 million, up from $5.5 million year-over-year, reflecting increased R&D and G&A expenses.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced CEO Jonathan Violin, Ph.D., will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 8:50 AM EST. He will also participate in fireside chats at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 AM GMT, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:55 AM EST. The company's lead program, VRDN-001, targets insulin-like growth factor-1 receptor for treating thyroid eye disease (TED), an autoimmune condition that can lead to vision complications.
Viridian Therapeutics announced the submission of an investigational new drug (IND) application to the FDA for its VRDN-001 program, targeting Thyroid Eye Disease (TED). This milestone aims to initiate a Phase 1/2 clinical trial, with proof of concept data expected in Q2 2022. VRDN-001 is an anti-IGF-1R monoclonal antibody, previously tested in over 100 oncology patients. The company believes this therapy could significantly improve TED symptoms, including proptosis and double vision, addressing a critical need in an underserved patient population.
Viridian Therapeutics (NASDAQ: VRDN) has announced the presentation of two posters featuring preclinical data on its drug candidates, VRDN-001 and VRDN-002, at the 90th Annual Meeting of the American Thyroid Association from September 30 to October 3, 2021. The posters focus on VRDN-002's pharmacokinetic profile and clinical promise as a second-generation IGF-1R antagonist for Thyroid Eye Disease, and the characterization of VRDN-001 as a potent anti-IGF-1R inhibitory antibody. These developments signal ongoing advancements in treatment options for patients with thyroid eye disease.